Where to find opportunities amid the trade war turmoil
We explore whether it might be time to buy the likes of CBA (ASX:CBA), BHP Group (ASX:BHP), Santos (ASX:STO), and Woodside (ASX:WDS).
Market Cap $72.42M
!
Corporate Spotlight
An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight
Recce accelerates commercialisation
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 28.5¢ | Day High | 29.0¢ | Day Low | 28.0¢ | |||
| Daily Volume | 92674 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 9 | 28.0¢ | 131092 | 1 | 29.0¢ | 63653 | |
Directors & Senior Management
| Mr. James Hamilton Bray Graham | Chief Executive Officer, Managing Director, Executive Director |
| Mr. Justin Reynolds | Chief Financial Officer |
| Ms. Michele Keryn Dilizia | Chief Scientific Officer, Executive Director |
| Dr. Philip Sutton | Vice President of Translational Sciences |
| Dr. Justin Ward | Executive Director and Principal Quality Chemist |
| Mr. Daniel Astudillo | Head of Marketing |
| Mr. Thomas Jarrett | Operations Manager |
| Ms. Maggie Niewidok | Company Secretary |
| Dr. John Prendergast | Independent Non- Executive Chairman of the Board |
| Mr. Alistair McKeough | Non-Executive Director |
| Dr. Alan William Dunton | Non-Executive Independent Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.42M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 28.0¢ | $26.74K | 92.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 131092 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 63653 | 1 |
View Market Depth
| Last trade - 16.10pm 25/04/2025 (20 minute delay) ? |
| RCE (ASX) Chart |
